Health and Healthcare
Biotech Monday (CRIS, CGRB, EXEL, MNKD, PDLI, SQNM, TCM)
Published:
Curis Inc. (NASDAQ: CRIS) shares down 18% after development partner Wyeth terminated their contract that focused on cancer treatment developments. Shares are down $0.29 to $1.14. The 52 week range is $0.86 to $2.35.
Cougar Biotechnology, Inc. (NASDAQ: CGRB) down 23% to $17.75.
Exelixis (NASDAQ: EXEL) hit a new 5 year low this morning. Its down 7% to $5.38 on a 52 week low of $5.67 to $12.77. No special reason for the downturn aside from a market wide lack of interest in developmental-stage drugs.
MannKind Corp. (NASDAQ: MNKD) downgrades and fears of ending inhaled insulin development lead to a new all-time low. Shares are down 18% at $4.52 in mid-day trading. The 52 week range is $5.25 to $15.99.
PDL BioPharma (NASDAQ: PDLI) fell another 8% after the recent drops after it canceled its sale last week. Its shares hit lows of $10.12, another 52-week low.
Sequenom Inc. (NASDAQ: SQNM) down 17% on no new news. Shares are trading at $5.47 with a 52 week range of $2.93 to $11.63.
Tongjitang Chinese Medicines Co. (NYSE: TCM) shares are up over 33% to $8.83 in mid-day trading on news that the CEO and another board director submitted a proposal to acquire all outstanding shares and take the company private. The 52 week range is $6.57 to $12.88.
Rachel Lopez
March 10, 2008
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.